Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults with mild to severe eczema
Potent probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Adverse effects ‐ burning · people with atopic dermatitis
1 finding from 1 review
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 2.91 [1.6, 5.28]
1 study · 371 participants
Moderate
RR 4.59 [3.1, 6.78]
1 study · 377 participants
Moderate
RR 3.79 [2.99, 4.81]
1 study · 972 participants
Moderate
Participant's self‐assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.1% may leads to higher participant's self‐assessment of global response of improvement compared with corticosteroids (low certainty).
1 finding from 1 review
Change in patient‐reported symptom scores (lower is favored) · people with dry eye
Steroids showed no clear difference in change in patient‐reported symptom scores (lower is favored) compared with lubricants (moderate certainty).
1 finding from 1 review
Change in TBUT (seconds) (longer is favored) · people with dry eye
Steroids showed no clear difference in change in TBUT (seconds) (longer is favored) compared with cyclosporine A (low certainty).
1 finding from 1 review
Change in fluorescein corneal staining scores (lower is favored) · people with dry eye
Steroids showed no clear difference in change in fluorescein corneal staining scores (lower is favored) compared with cyclosporine A (low certainty).
1 finding from 1 review
Change in tear osmolarity (mOsm/kg) (lower is favored) · people with dry eye
It is very uncertain whether steroids changes change in tear osmolarity (mOsm/kg) (lower is favored) compared with cyclosporine A (very low certainty).
1 finding from 1 review
Adverse effect: incident elevated IOP ( · people with dry eye
It is very uncertain whether steroids changes adverse effect: incident elevated IOP ( compared with cyclosporine A (very low certainty).
1 finding from 1 review
Adverse effect: cataract · people with dry eye
The review found no eligible studies for this question.
1 finding from 1 review
Change in patient‐reported quality of life scores · people with dry eye
The review found no eligible studies for this question.
1 finding from 1 review
Change in TBUT (seconds) (longer is favored) · people with dry eye
Steroids may leads to higher change in TBUT (seconds) (longer is favored) compared with lubricants (low certainty).
1 finding from 1 review
Change in fluorescein corneal staining scores (lower is favored) · people with dry eye
Steroids showed no clear difference in change in fluorescein corneal staining scores (lower is favored) compared with lubricants (moderate certainty).
1 finding from 1 review
Change in tear osmolarity (mOsm/kg) (lower is favored) · people with dry eye
It is very uncertain whether steroids changes change in tear osmolarity (mOsm/kg) (lower is favored) compared with lubricants (very low certainty).
1 finding from 1 review